Crescentic glomerulonephritis

Summary

Crescentic glomerulonephritis (MONDO:0001645) is a disease and 2 clinical trials. Top therapeutic interventions include pioglitazone. A subtype of acute proliferative glomerulonephritis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 2

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	crescentic glomerulonephritis
Mondo ID	MONDO:0001645
DOID	DOID:13139
NCIT	C35444
SNOMED CT	236398000
UMLS	C0403416
MedGen	96040
GARD	0022983
Is cancer (heuristic)	no

Also known as: crescentic glomerulonephritis · crescentic glomerulonephritis (disease)

Data availability: 1 HPO phenotype.

Disease family

This is a subtype of acute proliferative glomerulonephritis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › urinary system disorder › kidney disorder › nephritis › glomerulonephritis › proliferative glomerulonephritis › acute proliferative glomerulonephritis › crescentic glomerulonephritis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 2.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE3	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05946564	PHASE3	RECRUITING	A Trial to Evaluate the Efficacy of Pioglitazone to Promote Renal Tolerance in ANCA-associated Vasculitis - RENATO Trial
NCT03929887	Not specified	RECRUITING	KOrea Renal Biobank NEtwoRk System TOward NExt-generation Analysis

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
PIOGLITAZONE	4	1